Scholars Central

Conference abstractPublished 19 Nov 2012

Lessons/successes in fighting atherosclerosis using gene therapy of cytokines and their downstream genes in mice

Authors: Paul L. Hermonat

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Cardiovascular disease (CVD) remains one of the biggest killers of the aged. As CVD is a long term disease, usually taking decades to develop, therapeutic gene therapy (GT) could be a well matched treatment. Adeno-associated virus (AAV) gene delivery lasts years and is safe. This leaves the identification of appropriate genes for treating CVD as a main block for clinical CVD GT. Over the last few years we have been utilizing AAV-based GT to deliver anti-inflammatory cytokines, specifically interleukin 10 (IL-10) and transforming growth factor beta 1 (TGFbeta1). We have utilized the low density lipoprotein receptor knockout mouse (LDLR KO) on high cholesterol diet (HCD) to study these GTs as this model is believed the best in mimicking atherogenesis in humans on a high fat Western diet. As both TGFbeta1 and IL-10 are known to give complications when used clinically and/or in animal models, we have extended our search to the downstream signal transduction genes of IL-10 and TGFbeta 1. Such genes might be intracellular substitutes for these somewhat hazardous systemic cytokines. Obviously, the GT of intracellular proteins is a dramatically different approach to that of GT of secreted proteins. STAT3 was investigated as a substitute for IL-10, and while it did display therapeutic efficacy, its efficacy trended weaker than IL-10. Moreover, IL-10 plus STAT3 dual gene delivery gave no advantage over either gene delivered alone. Yet, STAT3 GT may still be a viable treatment as it might give fewer adverse reactions than IL-10. Moving on, SMAD3 GT was investigated as a substitute for TGFbeta1, and it also did display therapeutic efficacy. Additionally, and fortuitously, SMAD3 gene delivery did not display the well known attribute of promoting fibrosis, as is well known for TGFbeta1. Thus, SMAD3 may represent a successful GT approach with a significant advantage over its parent cytokine. We have also accumulated additional data on other cytokines/genes and their therapeutic value. Here, now, we are at a crossroads in anti-CVD GT. All our GT studies have been done on limiting atherogenesis, limiting the development of CVD, using one mouse model (LDLR KO mice on HCD). While our studies give us valuable information and are relevant, they may not represent the most accurate model for analyzing therapeutic GT strategies against established human CVD. Additional approaches and models, such as the use of different mouse models, disease-specific or cell-specific transcriptional promoters, and dual gene GT will be discussed

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Genetic Syndromes & Gene Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Genetic Syndromes & Gene Therapy
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Paul L. Hermonat”